Benralizumab 2 mg; Benralizumab 20 mg; Benralizumab 100 mg
Проводит МедИммун ЛЛC
Страница компанииA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01238861/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 964 чел. во всех странах исследования.
- Плановая дата окончания (08.2013) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 22
Критерии включения
- Age 18 through 75 years at the time of screening
- Adequate contraception from screening through end of trial
- Weight of more than (>) 45 kilogram (kg) but less than or equal to (<=) 150 kg (>100 pound \[lb\] but <=330 lb)
- History of physician-diagnosed asthma for at least 12 months prior to screening
- Physician prescribed daily use of medium-dose or high-dose inhaled corticosteroid(s) (ICS) plus long-acting beta 2 agonist (LABA) for at least 12 months prior to screening
- Willingness to switch to an ICS/LABA combination product
- Dose of other asthma controller medications must be stable for at least 30 days prior to screening
- At least 2 documented asthma exacerbations in the 12 months prior to screening that required use of a systemic corticosteroid burst
- For subjects 65 years of age or older, a chest x-ray (CXR) or chest computed tomography (CT) that is normal for an asthmatic population
- Ability and willingness to complete the study to Week 66, and if needed to Week 92.
Критерии невключения
- Known history of allergy or reaction to any component of the investigational product formulation
- History of anaphylaxis to any biologic therapy
- Unexplained diarrhea within 30 days prior to screening or diagnosis of helminth parasitic infestation within 6 months prior to screening
- Use of immunosuppressive medication within 3 months prior to screening. Chronic oral prednisone or equivalent up to 10 milligram (mg) daily or 20 mg every other day for asthma is allowed
- Oral corticosteroid burst or short-acting systemic corticosteroid within 30 days prior to screening or during the screening/run-in period
- Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 30 days prior to the screening or during the screening/run-in period
- Receipt of immunoglobulin or blood products within 30 days prior to screening
- Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to screening, whichever is longer
- Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to screening, whichever is longer
- Previously received MEDI-563
- Any clinically relevant abnormal findings in physical examination
- Past history of clinically significant cardiac disease or any electrocardiogram (ECG) abnormality
- Breastfeeding or lactating women
- History of alcohol or drug abuse within 12 months prior to screening
- History of any known primary immunodeficiency disorder
- Positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol
- A positive human immunodeficiency virus (HIV) test or subject taking antiretroviral medications
- History of cigarette smoking more than or equal to (>=) 10 pack-years or smoking within 12 months prior to screening.
- Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma
- History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >=12 months prior to screening or other malignancies treated with apparent success with curative therapy >=5 years prior to screening
- Stable dose of allergy vaccination regimen for less than 30 days prior to screening
- Subjects unable to demonstrate acceptable inhaler and peak flow meter techniques.
Источник: ClinicalTrials.gov, NCT01238861 · запись обновлена в реестре 17 ноября 2016.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 16
- Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants — Week 1 up to Week 52
Цель исследования
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01238861 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.